Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Melphalan Flufenamide→

Melphalan Flufenamide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
380449-51-4
Molecular formula
C24H30Cl2FN3O3
Molecular weight
498.4 g/mol
Drug class
Peptide-conjugated alkylating antineoplastic agentmelphalan prodrug-like peptide conjugate
Mechanism of action
Melphalan flufenamide is a peptide-conjugated alkylating agent designed to be taken up by cells and cleaved by intracellular peptidases to release melphalan. Melphalan alkylates DNA, causing DNA crosslinking and inhibition of DNA synthesis and tumour-cell proliferation.
Indications / reported uses
  • Historical US indication: in combination with dexamethasone for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy and refractory to specified prior agents. US approval was withdrawn effective 23 February 2024; do not present it as a current US-authorised treatment.

Sources: Federal Register — FDA final decision withdrawing PEPAXTO approval, 18 April 2024 · FDA Orphan Drug database — Melphalan flufenamide · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Peptide-conjugated alkylating antineoplastic agent; melphalan prodrug-like peptide conjugate

Mechanism of action

Melphalan flufenamide is a peptide-conjugated alkylating agent designed to be taken up by cells and cleaved by intracellular peptidases to release melphalan. Melphalan alkylates DNA, causing DNA crosslinking and inhibition of DNA synthesis and tumour-cell proliferation.

General use cases

  • Historical US indication: in combination with dexamethasone for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy and refractory to specified prior agents. US approval was withdrawn effective 23 February 2024; do not present it as a current US-authorised treatment.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Melphalan Flufenamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Melphalan Flufenamide Permitted Daily Exposure (PDE) report (the Melphalan Flufenamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Melphalan Flufenamide Occupational Exposure Limit (OEL) report (the Melphalan Flufenamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.